References
Bouchard L, Gelinas C, Asselir C and Bastin M (1984) Tumorigenic activity of Polyoma virus and SV40 DNAs in newborn rodents. Virology 135: 53–64.
Committee for Proprietory Medicinal Products (CPMP) (1991) Note for Guidance. Validation of Virus Removal and Inactivation Procedures. Biologicals 19: 247–251.
Land H, Parada LF and Weinberg RA (1983) Cellular oncogenes and multistep carcinogenesis. Science 222: 771–778.
Petricciani JC (1995) The acceptability of continuous cell lines: A personal & historical perspective. This volume
Shadle PJ, McAllister PR, Smith TM and Lubiniecki AS (1995) Viral validation strategy for recombinant products derived from established animal cell lines. This volume.
WHO Study Group (1987) Acceptability of cell substrates for production of biologicals. Geneva: World Health Organization Technical Report Series 747: 1–29.
Willkommen H and Löwer J (1993) Theoretical considerations on viral inactivation or elimination. In: Brown F. (ed.), Virological Safety Aspects of Plasma Derivatives. Developments in Biological Standardization, Basel, Karger, vol. 81, pp 109–116.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Löwer, J. Acceptability of continuous cell lines for the production of biologicals. Cytotechnology 18, 15–20 (1995). https://doi.org/10.1007/BF00744315
Issue Date:
DOI: https://doi.org/10.1007/BF00744315